Sign up to save your podcasts
Or
Share Overcoming EGFR Resistance With HER3-Directed ADCs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Overcoming EGFR Resistance With HER3-Directed ADCs
CME credits: 0.75
Valid until: 17-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-egfr-resistance-with-her3-directed-adcs/26457/
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.75
Valid until: 17-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/overcoming-egfr-resistance-with-her3-directed-adcs/26457/
Since the development of this educational activity, the Biologics License Application (BLA) seeking accelerated approval for patritumab deruxtecan (HER3-DXd), based on the HERTHENA-Lung01 Phase 2 trial for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies, has been voluntarily withdrawn.
This 6-episode program will guide healthcare professionals who treat advanced non-small cell lung cancer (NSCLC) through the biology of HER3 overexpression to broaden their understanding of its potential as a therapeutic target in EGFR-resistant advanced NSCLC. Tune in to enhance your confidence in applying scientific evidence to the creation of effective treatment strategies and develop evidence-based approaches for implementing novel HER3-directed antibody-drug conjugates (ADCs). Our experts also focus on the adoption of a team-based approach to help you monitor and manage treatment-related adverse events associated with HER3-directed ADCs.